ID | 118971 |
著者 | |
キーワード | Astaxanthin
Anti-aging medicine
oral hypoglycemic agent
Imeglimin
|
資料タイプ |
学術雑誌論文
|
抄録 | Latest Standards of Medical Care in Diabetes-2022 was presented from American Diabetes Association (ADA) on Jan 2022. A topic of Oral Hypoglycemic Agent (OHA) has been imeglimin. It may work through multiple action mechanism such as increasing insulin secretion, decreasing β-cell dysfunction, and preventing death of epithelial cells. Clinically, it decreases HbA1c by 0.5-1.0% for 1000mg twice a day. Diabetes and anti-aging medicine have common background pathophysiologically. Astaxanthin (AX) is the nephroprotective as mitochondrial regulator. AX-functioning mechanism includes to ameliorate insulin resistance and glucose intolerance. Imeglimin normalizes insulin sensitivity and glucose tolerance with maintaining mitochondrial function, suggesting common mechanism.
|
掲載誌名 |
Edelweiss Journal of Biomedical Research and Review
|
ISSN | 26902613
|
出版者 | Edelweiss Publications
|
巻 | 4
|
号 | 1
|
開始ページ | 1
|
終了ページ | 2
|
発行日 | 2022-06-23
|
権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
出版社版DOI | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|